Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 7:19 PM
Ignite Modification Date: 2025-12-25 @ 4:58 PM
NCT ID: NCT02242903
Description: None
Frequency Threshold: 5
Time Frame: None
Study: NCT02242903
Study Brief: A Study of LY3079514 in Healthy Participants
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Placebo Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion. None None 0 12 1 12 View
LY3079514 (LY) Cohort 1 7 mg single dose of LY3079514 administered by SC injection during a single occasion None None 0 6 4 6 View
LY Cohort 2 21 mg single dose of LY3079514 administered by SC injection during a single occasion None None 0 6 1 6 View
LY Cohort 3 70 mg single dose of LY3079514 administered by SC injection during a single occasion None None 0 6 3 6 View
LY Cohort 4 210 mg single dose of LY3079514 administered by SC injection during a single occasion None None 0 6 4 6 View
LY Cohort 5 70 mg single dose of LY3079514 administered IV during a single occasion None None 0 6 3 6 View
LY Cohort 6 210 mg single dose of LY3079514 administered IV during a single occasion None None 0 6 4 6 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Eye swelling SYSTEMATIC_ASSESSMENT Eye disorders MedDRA 17.0 View
Periorbital oedema SYSTEMATIC_ASSESSMENT Eye disorders MedDRA 17.0 View
Generalised oedema SYSTEMATIC_ASSESSMENT General disorders MedDRA 17.0 View
Oedema SYSTEMATIC_ASSESSMENT General disorders MedDRA 17.0 View
Laryngitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 17.0 View
Upper respiratory tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 17.0 View
Laceration SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA 17.0 View
Bone pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 17.0 View
Costochondritis SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 17.0 View
Tendon pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 17.0 View
Lethargy SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 17.0 View
Postmenopausal haemorrhage SYSTEMATIC_ASSESSMENT Reproductive system and breast disorders MedDRA 17.0 View
Premenstrual headache SYSTEMATIC_ASSESSMENT Reproductive system and breast disorders MedDRA 17.0 View
Dyspnoea SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 17.0 View
Haemoptysis SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 17.0 View
Nasal congestion SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 17.0 View
Sinus congestion SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA 17.0 View
Pruritus generalised SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA 17.0 View
Rash erythematous SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA 17.0 View
Skin irritation SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA 17.0 View
Eyelid oedema SYSTEMATIC_ASSESSMENT Eye disorders MedDRA 17.0 View
Abdominal pain lower SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 17.0 View
Instillation site bruise SYSTEMATIC_ASSESSMENT General disorders MedDRA 17.0 View
Oedema peripheral SYSTEMATIC_ASSESSMENT General disorders MedDRA 17.0 View
Urinary tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 17.0 View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 17.0 View